Anti-diabetic Effects of Persimmon Leaf Extract
Not Applicable
Completed
- Conditions
- Prediabetes
- Registration Number
- NCT02706821
- Lead Sponsor
- Chonbuk National University Hospital
- Brief Summary
The investigators performed a 8-week, randomized, double-blind, placebo-controlled crossover human trial to evaluate the efficacy and safety of persimmon leaf extract on blood glucose. The investigators measures changes in diabetes associated parameters, including fasting blood glucose, postprandial blood glucose, insulin, C-peptide and HbA1c.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
- Age 20-75 years
- Fasting blood glucose (FPG) 100~140 mg/dL or postprandial blood glucose (PPG) 140~250 mg/dL
Exclusion Criteria
- FPG more than 140 mg/dL
- 2h PPG more than 200 mg/dL
- Type 1 diabetes or HbA1c more than 9.0%
- treatment with corticosteroids within the past 4 weeks
- cardiovascular disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Fasting and postprandial plasma glucose baseline day 57, 85 and 141
- Secondary Outcome Measures
Name Time Method Interleukin-6 (IL-6) baseline and day 57, 85 and 141 Glycated hemoglobin (HbA1c) baseline and day 57, 85 and 141 adiponectin baseline and day 57, 85 and 141 leptin baseline and day 57, 85 and 141 Fasting plasma insulin baseline and day 57, 85 and 141 Tumor necrosis factor alpha (TNF-α) baseline and day 57, 85 and 141 Monocyte chemoattractant protein-1 (MCP-1) baseline and day 57, 85 and 141 C-peptide baseline and day 57, 85 and 141 Markers of Inflammation baseline and day 57, 85 and 141 resistin baseline and day 57, 85 and 141